1. Scrip
  2. >>Conferences
  3. >>ASCO

Roche Hopes To Gain Broad Market For Tecentriq In Adjuvant NSCLC

Interim ASCO Data Show Improvement in PD-L1 Expressors, All-Comers

 
• By Alaric DeArment

An executive told Scrip the company hopes to target all-comers as well as PD-L1-positive patients.

Doctor examining at lungs radiograph x-ray film of patient in operation room. medical concept.
Roche unveiled data from its Phase III study of Tecentriq in adjuvant NSCLC at ASCO • Source: Shutterstock

Roche Holding AG’s Genentech, Inc. subsidiary has its eye on an accelerated approval for Tecentriq (atezolizumab) in the adjuvant setting of non-small cell lung cancer (NSCLC) with interim Phase III trial results that could make it the first immune checkpoint inhibitor in the setting.

The company announced 19 May data from the 1,005-patient IMpower010 study, which the company will present in an oral session at the American Society of Clinical Oncology annual meeting on 6 June

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASCO

More from Conferences